Clinical Trials Directory

Trials / Completed

CompletedNCT02140827

Instant Messaging Program (Wechat) Improve the Quality of Bowel Preparation

Communication Through Instant Messaging Program for the Improvement of Bowel Preparation: a Two Centers Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
770 (actual)
Sponsor
Air Force Military Medical University, China · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Colonoscopy is the gold standard in the diagnosis of colorectal disease. The success of colonoscopy depends on high-quality bowel preparation by patients. Inadequate bowel cleansing reduces the cecal intubation rate, and the polyp detection rate (PDR). It also increases costs, mostly due to repeated procedures. The quality of bowel cleansing has remained suboptimal even though numerous different products and regimens have been tested and compared in no fewer than six meta-analyses. Therefore, a completely different approach to improve bowel cleansing is welcome. Here the investigators assume that instant messaging program (Wechat) delivery the detail and FAQ (Frequently Asked Questions) of bowel preparation instructions would improve the quality of the bowel preparation. The Wechat program has some advantages, 1. Wechat supports over 400 million users, nearly half of the mobile subscribers population in China; 2. Wechat provided a real time communications including voice messages, pictures and text exchange timely; 3.Compare with telephone, Wechat is economical of both time and money; 4. Compare with bowel preparation instructional software and litera or cartoon educational booklet, Wechat is more interactive and responsive.

Conditions

Interventions

TypeNameDescription
OTHERIMP interactive educationThe detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.

Timeline

Start date
2014-05-01
Primary completion
2014-12-01
Completion
2014-12-01
First posted
2014-05-16
Last updated
2014-12-23

Locations

3 sites across 1 country: China

Source: ClinicalTrials.gov record NCT02140827. Inclusion in this directory is not an endorsement.